MATTHEW JOHN DURING
Medical Practice in Weston, CT
License number
Pennsylvania MD069648L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Weston, CT 06883
Pennsylvania
Pennsylvania
Personal information
See more information about MATTHEW JOHN DURING at radaris.comName
Address
Phone
14 Cedar Ln, Weston, CT 06883
1512 Spruce St APT 2901, Philadelphia, PA 19102
2021 Delancey St, Philadelphia, PA 19103
14 Cedar Ln, Weston, CT 06883
14 Cedar Hls, Weston, CT 06883
Professional information
See more information about MATTHEW JOHN DURING at trustoria.com
Aav-Mediated Delivery Of Dna To Cells Of The Nervous System
Aav-Mediated Delivery Of Dna To Cells Of The Nervous System
US Patent:
6503888, Jan 7, 2003
Filed:
Apr 13, 2000
Appl. No.:
09/548176
Inventors:
Michael G. Kaplitt - New York NY
Matthew J. During - Weston CT
Matthew J. During - Weston CT
Assignee:
The Rockefeller University - New York NY
Yale University - New Haven CT
Yale University - New Haven CT
International Classification:
A01N 4304
US Classification:
514 44, 4353201, 435455, 435456
Abstract:
The invention relates to a method of delivering exogenous DNA to a target cell of the mammalian central nervous system using an adeno-associated virus (AAV)-derived vector. Also included in the invention are the AAV-derived vectors containing exogenous DNA which encodes a protein or proteins which prevent or treat nervous system disease, and a method of prevent or treating such disease.
Aav-Mediated Delivery Of Dna To Cells Of The Nervous System
Aav-Mediated Delivery Of Dna To Cells Of The Nervous System
US Patent:
6180613, Jan 30, 2001
Filed:
Jun 6, 1995
Appl. No.:
8/467044
Inventors:
Michael G. Kaplitt - New York NY
Matthew J. During - Weston CT
Matthew J. During - Weston CT
Assignee:
The Rockefeller University - New York NY
Yale University - New Haven CT
Yale University - New Haven CT
International Classification:
A01N 4304, A61K 3170, C12N 1563, C12N 1500
US Classification:
514 44
Abstract:
The invention relates to a method of delivering exogenous DNA to a target cell of the mammalian central nervous system using an adeno-associated virus (AAV)-derived vector. Also included in the invention are the AAV-derived vectors containing exogenous DNA which encodes a protein or proteins which treat nervous system disease, and a method of treating such disease.